Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib plus capecitabine vs capecitabine in previously treated breast cancer
2006-004624-36Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Jan 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in breast cancer comparing Sunitinib plus capecitabine with Capecitabine alone (2 arms). Primary endpoint: Progression-free survival. Started Jan 2007; status: terminated.
02
Drugs
sunitinibcapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2006-004624-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004624-36.